Consistent results were observed in stratified analyses according to etiologic stroke subtype, stroke severity, stroke location, age, and recanalization therapy groups, indicating that BD-tau may serve as a biomarker of outcome in most ischemic stroke subgroups. This evidence concerns the gene MAPT and ischemic stroke.